TO THE EDITOR:

The Bruton tyrosine kinase (BTK) inhibitor ibrutinib is used to treat indolent B-cell malignancies and chronic graft-versus-host disease (cGVHD). The potential for ibrutinib to abrogate pulmonary inflammatory cytokines, lung injury, and death was demonstrated in a highly relevant lethal flu animal model.^[@B1]^ Therefore, we sought to clarify the impact of ibrutinib in COVID-19 patients. We care for 600 to 800 Waldenstrom macroglobulinemia (WM) patients each year, ∼300 of whom are on a BTK inhibitor. We identified 6 patients receiving ibrutinib for WM who were diagnosed with COVID-19; these patients consented to the use of their data. Their clinical characteristics appear in [Table 1](#T1){ref-type="table"}. Their median age was 66 years, and 5 were on the recommended treatment dose of 420 mg/d; the sixth patient was on a reduced dose of 140 mg/d because of arthralgias. For all patients, the median time on ibrutinib was 52 months. Their median time with COVID-19--related symptoms prior to diagnostic testing was 5 days, and the median time since diagnosis of COVID-19 was 22 days. All 6 patients experienced cough and fever as prodromal symptoms. The 5 patients on ibrutinib, 420 mg/d, did not experience dyspnea and did not require hospitalization. Their course was marked by steady improvement, and resolution or near resolution of COVID-19--related symptoms during the follow-up period.

###### 

Clinical characteristics of 6 patients with WM on ibrutinib with COVID-19 infection

  Demographics                                                  Patient 1   Patient 2   Patient 3   Patient 4   Patient 5   Patient 6
  ------------------------------------------------------------- ----------- ----------- ----------- ----------- ----------- ---------------
  Age, y                                                        65          61          72          67          71          58
  Sex                                                           M           M           F           F           M           M
  Time since B-cell diagnosis, mo                               39          54          95          202         52          107
  Received treatment prior to ibrutinib for WM                  No          No          Yes         Yes         No          Yes
  Time on ibrutinib, mo                                         39          54          83          50          47          85
  Dose of ibrutinib, mg/d                                       420         420         420         420         420         140-HELD-420
  **COVID-19 symptoms**                                                                                                     
   Time with symptoms prior to COVID-19 diagnostic testing, d   5           2           6           7           10          5
   Time since COVID-19 diagnostic testing, d                    24          20          17          28          13          29
   Cough                                                        Yes         Yes         Yes         Yes         Yes         Yes
   Fever                                                        Yes         Yes         Yes         Yes         Yes         Yes
   Dyspnea                                                      No          No          No          No          No          Yes
   Sore throat                                                  Yes         No          No          No          No          Yes
   Taste loss                                                   No          No          Yes         No          Yes         No
   Smell loss                                                   No          No          Yes         No          Yes         No
   Hospitalization                                              No          No          No          No          No          Yes
   Required ICU admission                                       Yes         No          No          No          No          Yes
   Required supplemental O2                                     No          No          No          No          No          Yes
   Required mechanical ventilation                              No          No          No          No          No          Yes
   Other COVID-19 symptoms                                      No          Anorexia    Diarrhea    Headache    No          No
   Other medication for COVID-19                                HCQ, AZ     NA          No          NA          No          HCQ, AZ, TOCI
  **Disposition**                                                                                                           
   COVID-19 symptoms resolved                                   No          Yes         Yes         Yes         Yes         No
   COVID-19 symptoms persist                                    Yes         No          Yes         Yes         No          Yes
   COVID-19 symptoms improved                                   Yes         Yes         Yes         Yes         Yes         Yes

140-HELD-420 denotes that this patient was on 140 mg/d of ibrutinib prior to hospitalization that was held upon admission; he experienced worsening hypoxia after ibrutinib was held and required mechanical ventilation, following which he was restarted on 420 mg/d of ibrutinib and showed rapid improvement in oxygenation.

AZ, azithromycin; F, female; HCQ, hydroxychloroquine; ICU, Intensive Care Unit; M, male; TOCI, tocilizumab.

The patient on reduced-dose ibrutinib (Patient 6; [Table 1](#T1){ref-type="table"}) experienced progressive dyspnea and hypoxia prompting hospitalization. Chest computed tomography showed bilateral ground glass opacities and a pleural effusion on admission prompting a hold on ibrutinib, during which his hypoxia acutely worsened, necessitating supplemental oxygen use. Hydroxychloroquine (HCQ) and azithromycin were administered. Azithromycin was stopped after 3 days because of wide QRS complex tachyarrhythmia; HCQ was given for a total of 5 days. Hypoxia worsened and fever persisted during HCQ course. Ibrutinib was restarted at 140 mg/d, and tocilizumab, 400 mg, was coadministered on hospital day 5 with improved oxygenation, as well as decreased C-reactive protein (CRP) levels (83 mg/L to 9 mg/L). IV immunoglobulin was also given on hospital days 6 through 10. On day 10 of hospitalization, the patient experienced worsening hypoxia that was accompanied by increased CRP (28 mg/L) and required mechanical ventilation. Given the lack of hypoxia in the other COVID-19--infected WM patients on full-dose ibrutinib, ibrutinib was increased to 420 mg/d on days 11 and 12. A rapid improvement in oxygenation followed, and the patient was successfully extubated late on day 12 and maintained oxygen saturations of 94% to 96% on 3 L/min supplemental oxygen by nasal cannula. The next day, supplemental oxygen was decreased to 2 L/min, with oxygen saturations of 96% to 98% and a CRP level of 10 mg/L. On day 14, oxygen saturation was 95% on room air, repeat CRP level was 6 mg/L, and he was discharged home off supplemental oxygen and on 420 mg/d of ibrutinib. Seven days later, he continues to do well, without fever, cough, or dyspnea at rest. He remains on ibrutinib, 420 mg/d, and is tolerating therapy well.

Pulmonary failure is the main cause of mortality related to COVID-19 infection.^[@B2],[@B3]^ Up to 80% of patients hospitalized for COVID-19 infection require supplemental oxygenation, of whom 30% to 40% may require mechanical ventilation.^[@B2],[@B4],[@B5]^ SARS-CoV-2 binds via the ACE2 receptor that is highly expressed on alveolar type II (ATII) cells in the lung.^[@B6]^ ATII cells constitute 5% to 15% of the lung epithelium. Although ATI cells are highly adapted for gas exchange, ATII cells have a specialized role in innate immune response.^[@B7][@B8]-[@B9]^ ATII cells express Toll-like receptors (TLRs) and can trigger inflammatory cytokines and chemoattractants in response to pathogens that recruit and activate other immune cells, including macrophages and neutrophils.^[@B7][@B8]-[@B9]^ Highly relevant to coronavirus infection, expression of proinflammatory and chemoattractant cytokines interleukin-1β (IL-1β), IL-6, IP-10/CXCL10, monocyte chemoattractant protein-1 (MCP-1), and tumor necrosis factor-α (TNF-α) was identified in ACE2^+^ cells from autopsy tissue of SARS-CoV-1--infected patients, which appeared to be causally related to the acute lung injury and pathogenesis observed with SARS-CoV-1.^[@B10]^ A similar profile of elevated cytokine levels was reported in the plasma of SARS-CoV-1 patients during the progressive and end stage of infection,^[@B11]^ which was consistent with an M1-polarized macrophage response.^[@B12]^

SARS-CoV-1 shares 86% homology with SARS-CoV-2. SARS-Cov-2 patients requiring intensive care also showed elevated plasma levels of inflammatory cytokines and chemoattractants, such as IL-2, IL-6, IL-7, IL-10, granulocyte colony-stimulating factor, IP-10/CXCL-10, MCP-1/CCL2, MIP-1a/CCL3, and TNF-α.^[@B13]^ The importance of inflammatory cytokines to lung injury in SARS-CoV-2--infected patients has been suggested by reports of benefit with IL-6 and IL-6 receptor--blocking antibodies, and clinical trials to examine their use have been initiated (NCT04317092, NCT04306705, NCT04315298).

We and other investigators previously showed that BTK and its upstream activator HCK were involved in TLR-mediated signaling.^[@B14][@B15]-[@B16]^ BTK and HCK are triggered by MYD88, a TLR adaptor protein that signals for all TLRs, with the exception of TLR3, in response to viral and bacterial pathogens, including coronaviruses.^[@B17]^ ATII cells express TLRs, as do alveolar macrophages that coordinate inflammatory responses with ATII cells.^[@B7][@B8]-[@B9]^ As components of TLR/MYD88 signaling, BTK and HCK can drive inflammatory cytokine production through ERK1/2.^[@B18]^

In a transgenic mouse model, activated HCK overexpression promoted extensive pulmonary inflammation and an enhanced innate immune response, particularly in older mice.^[@B19]^ Elevated levels of TNF-α were identified in the bronchoalveolar lavage fluids of these mice following lipopolysaccharide challenge. The pulmonary pathology findings from these mice show great overlap with those from patients with COVID-19 infection, which included serous and fibrin exudation with alveolar infiltration consisting mostly of macrophages and monocytes.^[@B20]^

Ibrutinib is a highly potent covalent inhibitor of BTK (biochemical 50% inhibitory concentration \[IC~50~\], 0.5 nM). Ibrutinib is also a potent reversible inhibitor of HCK (IC~50~, 49 nM). The IC~50~ levels for BTK and HCK are within the pharmacologically attainable dosimetry of orally administered ibrutinib.^[@B16]^ Serially collected blood samples from patients with chronic lymphocytic leukemia (CLL), WM, and cGVHD on ibrutinib monotherapy showed marked reductions in proinflammatory and chemoattractant cytokines that greatly overlapped with those reported to be elevated in the plasma of SARS-CoV-1 and SARS-CoV-2 patients, as well as in ACE2^+^ cells from lung tissue of SARS-CoV-1 patients ([Table 2](#T2){ref-type="table"}).^[@B10],[@B11],[@B13],[@B21][@B22]-[@B23]^ In the ILLUMINATE randomized study, CLL subjects treated with ibrutinib immediately prior to infusion with obinutuzumab also showed significantly decreased levels of inflammatory cytokines associated with infusion-related reactions (a cytokine release syndrome).^[@B24]^ These findings are consistent with a shift from an M1- to an M2-polarized macrophage response following ibrutinib and are supported by preclinical and clinical studies showing dependence of macrophage lineage commitment on BTK function.^[@B25]^

###### 

Summary of proinflammatory and chemoattractant cytokine patterns in patients infected with SARS-CoV-1 and SARS-CoV-2 and following ibrutinib treatment in patients with CLL, WM, or and cGVHD

                       He et al^[@B10]^                         Jiang et al^[@B11]^                      Huang et al^[@B13]^                      Niemann et al^[@B21]^                              Greil et al^[@B24]^                                Vos et al^[@B22]^                                 Miklos et al^[@B23]^
  -------------------- ---------------------------------------- ---------------------------------------- ---------------------------------------- -------------------------------------------------- -------------------------------------------------- ------------------------------------------------- ----------------------------------------------------
  Patient population   CoV-1[\*](#TF2-1){ref-type="table-fn"}   CoV-1[\*](#TF2-1){ref-type="table-fn"}   CoV-2[\*](#TF2-1){ref-type="table-fn"}   CLL on ibrutinib[†](#TF2-2){ref-type="table-fn"}   CLL on ibrutinib[†](#TF2-2){ref-type="table-fn"}   WM on ibrutinib[†](#TF2-2){ref-type="table-fn"}   cGVHD on ibrutinib[†](#TF2-2){ref-type="table-fn"}
  Tissue               ACE2^+^ cells                            Plasma                                   Plasma                                   Plasma                                             Plasma                                             Plasma                                            Plasma
  GM-CSF                                                                                                 ↑                                                                                                                                                                                                **↓**
  IL-1β                ↑                                                                                                                                                                                                                                                                                  
  IL-2                                                                                                   **↑**                                                                                                                                                                                            ↓ (IL2RA)
  IL-6                 **↑**                                    **↑**                                                                             **↓**                                              **↓**                                              **↓**                                             
  IL-7                                                                                                   **↑**                                                                                                                                                                                            
  IL-8                                                          **↑**                                                                             **↓**                                              **↓**                                              **↓**                                             **↓**
  IL-10                                                                                                  **↑**                                    **↓**                                              **↓**                                              Variable                                          
  IP-10/CXCL10                                                  **↑**                                    **↑**                                    **↓**                                                                                                 **↓**                                             **↓**
  MCP-1/CCL2           **↑**                                    **↑**                                    **↑**                                    **↓**                                              **↓**                                                                                                **↓**
  MIP-1A/CCL3                                                                                            **↑**                                    **↓**                                                                                                                                                   **↓**
  MIP-1B/CCL4                                                                                            **↑**                                    **↓**                                                                                                 **↓**                                             **↓**
  TNF-α                **↑**                                                                                                                      **↓**                                              **↓**                                              **↓**                                             **↓**

↑, denotes elevated in patients with SARS-CoV-1 or SARS-CoV-2; ↓, denotes levels decreased or inhibited in patients with the indicated condition with ibrutinib treatment; GM-CSF, granulocyte-macrophage colony-stimulating factor.

Patients infected with SARS-CoV-1 or SARS-CoV-2.

Patients with CLL, WM, or cGVHD.

The potential for ibrutinib to abrogate lung injury and death was also demonstrated in an experimental model wherein mice challenged with a lethal intranasal inoculum of a mouse-adapted strain of H1N1 influenza virus were protected against lung injury. Control mice developed respiratory failure, along with histological and computed tomography findings consistent with lung injury, in sharp contrast to the mice that received ibrutinib.^[@B1]^ Control mice also lost weight and died, whereas those treated with ibrutinib recovered their weight after a brief loss, and all survived.^[@B1]^ Notably, mice treated with ibrutinib also showed decreased inflammatory cell infiltration, as well as proinflammatory cytokines in lung tissues, that included proinflammatory and chemoattractant cytokines, such as IL-1β, IL-6, KC/CXCL1, TNF-α, and MCP-1, in SARS-Cov-1 and SARS-CoV-2 patients.^[@B1]^ The findings provide rationale that an exaggerated cytokine release syndrome triggered in ATII cells and resident macrophages by SARS-CoV-2 may underlie pulmonary injury associated with COVID-19.

Therefore, ibrutinib, and possibly other BTK inhibitors, may provide protection against lung injury and even improve pulmonary function in hypoxic patients with COVID-19, as we observed in this series of WM patients on ibrutinib. These findings should be considered hypothesis generating and preliminary in nature. Patients on ibrutinib, and possibly other BTK inhibitors, may well benefit with continuation of their therapy, despite the diagnosis of COVID-19. It will be important to validate these findings in other patient populations who are taking BTK inhibitors, including CLL patients. Clinical trials examining the benefit of BTK inhibitors are being initiated by us and other investigators in COVID-19 patients in pulmonary distress, and the outcome of these prospective randomized studies will be needed to confirm these preliminary observations.
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